Volume 7, Issue 3 (Autumn 2004)
J Arak Uni Med Sci 2004, 7(3): 27-33 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mansoori S, Attari A, Amini M, Bagherian R. A Comparison of Diabetes Mellitus Incidence Between Atypical and Typical Antipsychotic Drugs in Janbazan With Mental Disorder. J Arak Uni Med Sci 2004; 7 (3) :27-33
URL: http://jams.arakmu.ac.ir/article-1-6809-en.html
URL: http://jams.arakmu.ac.ir/article-1-6809-en.html
Abstract: (2007 Views)
Introduction: Atypical antipsychotic drugs in comparison with typical antipsychotics produce fewer extra pyramidal symptoms at clinically effective doses. However there has also been a growing number of reports of new onset diabetes mellitus in patients receiving these drugs. The aim of this study was the comparison of diabetes mellitus incidence in mentally janbazan (Iran-Iraq war veterans) undertaken typical with atypical antipsychotics.
Materials and Methods: In this study the incidence of new onset Dm was assessed in 200 subjects referred to Amiralmomenin clinic, Isfahan, Iran. Every patient was included in this study if he was receiving atypical or typical antipsychotic drugs or combination of both types, at least for one year. Sampling was convenient. Fasting blood sugar, triglyceride and cholesterol before taking the drugs was documented in their records. New onset DM was defined based on 126 mg/dl or more for FBS which was confirmed with GTT. For comparison of FBS mean pre and post interventions, NIDDM incidence, the relation of background variables with NIDDM and the relation of NIDDM incidence with dosages and duration of drug therapy, paired t-test, chi-square, logistic regression and ANOVA were used.
Results: Subjects were divided into three groups based on the type of drugs used 135 patients using typical antipsychotics (chlorpromazine, perphenazine, haloperidol, …), 39 patients using atypical antipsychotics (clozaoine & riaperidon) and 26 patients receiving combination of drugs. It was found that DM developed following treatment in three groups were 12.8%, 6.7% and 3.8% respectively. There was no significant differences between three groups regarding the incidence of new onset DM.
Conclusion: Findings showed that patients treated with antipsychotic drugs had a moderately increased risk of DM especially with atypical antipsychotics. It is suggested to evaluate every patients before treatment for risk factors of DM.
Materials and Methods: In this study the incidence of new onset Dm was assessed in 200 subjects referred to Amiralmomenin clinic, Isfahan, Iran. Every patient was included in this study if he was receiving atypical or typical antipsychotic drugs or combination of both types, at least for one year. Sampling was convenient. Fasting blood sugar, triglyceride and cholesterol before taking the drugs was documented in their records. New onset DM was defined based on 126 mg/dl or more for FBS which was confirmed with GTT. For comparison of FBS mean pre and post interventions, NIDDM incidence, the relation of background variables with NIDDM and the relation of NIDDM incidence with dosages and duration of drug therapy, paired t-test, chi-square, logistic regression and ANOVA were used.
Results: Subjects were divided into three groups based on the type of drugs used 135 patients using typical antipsychotics (chlorpromazine, perphenazine, haloperidol, …), 39 patients using atypical antipsychotics (clozaoine & riaperidon) and 26 patients receiving combination of drugs. It was found that DM developed following treatment in three groups were 12.8%, 6.7% and 3.8% respectively. There was no significant differences between three groups regarding the incidence of new onset DM.
Conclusion: Findings showed that patients treated with antipsychotic drugs had a moderately increased risk of DM especially with atypical antipsychotics. It is suggested to evaluate every patients before treatment for risk factors of DM.
Subject:
General
Received: 2021/01/29 | Accepted: 2004/10/1
Received: 2021/01/29 | Accepted: 2004/10/1
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
